Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001
Titel:
Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001
Auteur:
Marth, Christian Tarnawski, Rafal Tyulyandina, Alexandra Pignata, Sandro Gilbert, Lucy Kaen, Diego Rubio, M Jesús Frentzas, Sophia Beiner, Mario Magallanes-Maciel, Manuel Farrelly, Laura Choi, Chel Hun Berger, Regina Lee, Christine Vulsteke, Christof Hasegawa, Kosei Braicu, Elena Ioanna Wu, Xiaohua McKenzie, Jodi Lee, John J Makker, Vicky
Verschenen in:
International journal of gynecological cancer
Paginering:
Jaargang 32 () nr. 1 pagina's 93-100
Jaar:
2022
Inhoud:
Uitgever:
IGCS and ESGO 2022. Re-use permitted under CC BY. Published by BMJ.